Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting
06 déc. 2020 08h00 HE
|
Constellation Pharmaceuticals , Inc.
67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeksCPI-0610 demonstrated activity, both as a monotherapy and as add on to...
Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610 Presented at ASH Meeting
23 nov. 2020 13h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results
29 oct. 2020 07h00 HE
|
Constellation Pharmaceuticals , Inc.
MANIFEST data update planned for the American Society of Hematology (ASH) meeting in December CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a...
Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results
19 oct. 2020 14h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
09 sept. 2020 15h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...
Constellation Pharmaceuticals Announces Second-Quarter 2020 Financial Results, Provides Regulatory Update
05 août 2020 07h00 HE
|
Constellation Pharmaceuticals , Inc.
Constellation has aligned with the FDA on the design of MANIFEST-2, the pivotal Phase 3 clinical trial for CPI-0610 expected to begin in 2H20Constellation plans to explore additional indications for...
Constellation Pharmaceuticals to Host Conference Call to Discuss Second Quarter 2020 Results
31 juil. 2020 12h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock
16 juin 2020 20h27 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock
15 juin 2020 16h01 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise
12 juin 2020 02h30 HE
|
Constellation Pharmaceuticals , Inc.
Spleen response rates in first-line patients at 12 weeks and 24 weeks in line with previously reported data and differentiated from standard of careSpleen responses demonstrated in...